Literature DB >> 16835725

The effect of prior biopsy scheme on prostate cancer detection for repeat biopsy population: results of the 14-core prostate biopsy technique.

Saadettin Yilmaz Eskicorapci1, Fuad Guliyev, Ekrem Islamoglu, Ali Ergen, Haluk Ozen.   

Abstract

OBJECTIVES: To evaluate the diagnostic performance of 14-core repeat biopsy protocol and the impact of prior biopsy scheme on repeat prostate biopsy group.
METHODS: 211 patients had repeat biopsy using 14-core protocol consisting of 10-core peripheral zone (classical sextant+4 lateral peripheral cores) and 4-core transitional zone (TZ) biopsies. The diagnostic yield was determined both in patients who had previously undergone sextant or 10-core biopsy protocol.
RESULTS: Overall cancer detection rate was 25.6%. 14-core biopsy technique detected cancer in 36.1 and 18.7% of the patients who had a previous sextant biopsy and 10-core biopsy protocol, respectively (P = 0.005). Patients with and without high-grade prostatic intraepithelial neoplasia (HGPIN) in the previous sextant biopsy had 56.5 and 28.3% cancer detection rates on the subsequent extended biopsy, respectively (P = 0.017) Patients who had previous 10-core biopsy with and without HGPIN revealed 22.9 and 17.2% cancer detection rates, respectively (P = 0.465) Additional four lateral peripheral cores detected 33% (3/30) and 17% (4/24) of cancers in patients with previous sextant and 10-core biopsy, respectively. 3.7% of the patients had tumor only in the TZ and none of them had prior extended biopsy.
CONCLUSIONS: The yield of extended 14-core repeat biopsy protocol was higher in patients with previous negative sextant biopsy compared to the patients with previous negative 10-core biopsy. HGPIN history found on previous sextant biopsy was a strong cancer predictor on repeat biopsy; same was not true for the patients with previous 10-core biopsy. The yield of lateral peripheral cores and TZ biopsies were lower in patients with prior negative extended biopsy.

Entities:  

Mesh:

Year:  2006        PMID: 16835725     DOI: 10.1007/s11255-006-9009-5

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  19 in total

1.  Prostate biopsy: how many cores are enough?

Authors:  Joseph C Presti
Journal:  Urol Oncol       Date:  2003 Mar-Apr       Impact factor: 3.498

2.  Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies.

Authors:  C S Stewart; B C Leibovich; A L Weaver; M M Lieber
Journal:  J Urol       Date:  2001-07       Impact factor: 7.450

3.  Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.

Authors:  H B Carter; J I Epstein; D W Chan; J L Fozard; J D Pearson
Journal:  JAMA       Date:  1997-05-14       Impact factor: 56.272

4.  Risk of prostate cancer on first re-biopsy within 1 year following a diagnosis of high grade prostatic intraepithelial neoplasia is related to the number of cores sampled.

Authors:  Mehsati Herawi; Hillel Kahane; Christina Cavallo; Jonathan I Epstein
Journal:  J Urol       Date:  2006-01       Impact factor: 7.450

5.  A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session.

Authors:  Ernesto Lopez-Corona; Makoto Ohori; Peter T Scardino; Victor E Reuter; Mithat Gonen; Michael W Kattan
Journal:  J Urol       Date:  2003-10       Impact factor: 7.450

6.  Results of the 5 region prostate biopsy method: the repeat biopsy population.

Authors:  Jeffrey C Applewhite; Brian R Matlaga; David L McCullough
Journal:  J Urol       Date:  2002-08       Impact factor: 7.450

7.  Indications for ultrasound guided transition zone biopsies in the detection of prostate cancer.

Authors:  P D Lui; M K Terris; J E McNeal; T A Stamey
Journal:  J Urol       Date:  1995-03       Impact factor: 7.450

8.  Impact of prior biopsy scheme on pathologic features of cancers detected on repeat biopsies.

Authors:  Y Mark Hong; Frank C Lai; Chris H Chon; John E McNeal; Joseph C Presti
Journal:  Urol Oncol       Date:  2004 Jan-Feb       Impact factor: 3.498

9.  An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer.

Authors:  Saadettin Yilmaz Eskicorapci; Dilek Ertoy Baydar; Cem Akbal; Mustafa Sofikerim; Mert Günay; Sinan Ekici; Haluk Ozen
Journal:  Eur Urol       Date:  2004-04       Impact factor: 20.096

10.  Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate.

Authors:  K K Hodge; J E McNeal; M K Terris; T A Stamey
Journal:  J Urol       Date:  1989-07       Impact factor: 7.450

View more
  6 in total

1.  Dutasteride for the prevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia: results of a phase III randomized open-label 3-year trial.

Authors:  Daimantas Milonas; Stasys Auskalnis; Giedrius Skulcius; Inga Gudinaviciene; Mindaugas Jievaltas; Steven Joniau
Journal:  World J Urol       Date:  2016-09-19       Impact factor: 4.226

2.  Is sampling transitional zone in patients who had prior negative prostate biopsy necessary?

Authors:  Bayram Dogan; Ege Can Serefoglu; Ali Fuat Atmaca; Abdullah Erdem Canda; Ziya Akbulut; M Derya Balbay
Journal:  Int Urol Nephrol       Date:  2012-03-15       Impact factor: 2.370

Review 3.  Precursor lesions to prostatic adenocarcinoma.

Authors:  Jonathan I Epstein
Journal:  Virchows Arch       Date:  2008-12-02       Impact factor: 4.064

4.  High-grade prostatic intraepithelial neoplasia.

Authors:  Joseph C Klink; Ranko Miocinovic; Cristina Magi Galluzzi; Eric A Klein
Journal:  Korean J Urol       Date:  2012-05-18

5.  Significance of atypical small acinar proliferation and high-grade prostatic intraepithelial neoplasia in prostate biopsy.

Authors:  Orhan Koca; Selahattin Calışkan; Metin İshak Oztürk; Mustafa Güneş; M Ihsan Karaman
Journal:  Korean J Urol       Date:  2011-11-17

6.  3-Tesla magnetic resonance imaging improves the prostate cancer detection rate in transrectral ultrasound-guided biopsy.

Authors:  Jie Chen; Xiao-Lei Yi; Li-Xin Jiang; Ren Wang; Jun-Gong Zhao; Yue-Hua Li; Bing Hu
Journal:  Exp Ther Med       Date:  2014-11-11       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.